This study was an external analysis of the viability of supporting oxytocin in the Uniject™ injection system as a niche product in both the public and private sectors globally. A major component of this analysis was to conduct separate market analyses of 30 countries identified by the US Agency for International Development as priority countries for maternal health interventions.
Corporate author(s): PATH
Publication date: June 2011
862 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA